Abstract:Aim: To construct a quantitative pharmacophore model of tubulin inhibitors and to discovery new leads with potent antitumor activities. Methods: Ligand-based pharmacophore modeling was used to identify the chemical features responsible for inhibiting tubulin polymerization. A set of 26 training compounds was used to generate hypothetical pharmacophores using the HypoGen algorithm. The structures were further validated using the test set, Fischer randomization method, leave-one-out method and a decoy set, and the best model was chosen to screen the Specs database. Hit compounds were subjected to molecular docking study using a Molecular Operating Environment (MOE) software and to biological evaluation in vitro . Results: Hypo1 was demonstrated to be the best pharmacophore model that exhibited the highest correlation coefficient (0.9582), largest cost difference (70.905) and lowest RMSD value (0.6977). Hypo1 consisted of one hydrogen-bond acceptor, a hydrogen-bond donor, a hydrophobic feature, a ring aromatic feature and three excluded volumes. Hypo1 was validated with four different methods and had a goodness-of-hit score of 0.81. When Hypo1 was used in virtual screening of the Specs database, 952 drug-like compounds were revealed. After docking into the colchicine-binding site of tubulin, 5 drug-like compounds with the required interaction with the critical amino acid residues and the binding free energies <-4 kcal/mol were selected as representative leads. Compounds 1 and 3 exhibited inhibitory activity against MCF-7 human breast cancer cells in vitro . Conclusion: Hypo1 is a quantitative pharmacophore model for tubulin inhibitors, which not only provides a better understanding of their interaction with tubulin, but also assists in discovering new potential leads with antitumor activities.

Structure-Based Pharmacophore Design And Virtual Screening For Novel Tubulin Inhibitors With Potential Anticancer Activity

Tubulin Inhibitors: Pharmacophore Modeling, Virtual Screening and Molecular Docking

In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening

Structure-based approaches for the design of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d][1,2,3]triazoles as tubulin polymerization inhibitors

Discovery of Novel Tubulin Polymerization Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone As Potent Tubulin Polymerization Inhibitors.

Combined Molecular Docking, 3D-QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine-binding Site.

Ligand- and Structural-Based Discovery of Potential Small Molecules That Target the Colchicine Site of Tubulin for Cancer Treatment.

Design, Synthesis, and Biological Evaluation of Novel Benzodiazepine Derivatives As Anticancer Agents Through Inhibition of Tubulin Polymerization in Vitro and in Vivo

Design, Synthesis and Biological Evaluation of Novel Dihydroquinolin-4(1H)-one Derivatives As Novel Tubulin Polymerization Inhibitors

Design, Synthesis and Anti-tubulin Activity of Novel Dinitro Diphenyl Ether Derivatives As Potent Anticancer Agent

Heterocyclic-Fused Pyrimidines As Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy

Design, Synthesis and Characterization of Potent Microtubule Inhibitors with Dual Anti-Proliferative and Anti-Angiogenic Activities

Synthesis, Molecular Docking and Biological Evaluation of 1-Phenylsulphonyl-2-(1-methylindol-3-yl)-benzimidazole Derivatives As Novel Potential Tubulin Assembling Inhibitors

Design, Synthesis, and Biological Evaluation of 4-Aryl-9h-carbazoles As Tubulin Polymerization Inhibitors with Potent Anticancer Activities

Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor

Optimization of Benzamide Derivatives As Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.

The discovery of potential tubulin inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies

Discovery of novel microtubule stabilizers targeting taxane binding site by applying molecular docking, molecular dynamics simulation, and anticancer activity testing

Design, synthesis, and bioevaluation of imidazo [1,2-a] pyrazine derivatives as tubulin polymerization inhibitors with potent anticancer activities.

Design and synthesis of novel 3-amino-5-phenylpyrazole derivatives as tubulin polymerization inhibitors targeting the colchicine-binding site